Posted by Michael Wonder on 07 Nov 2022
Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults
3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 adults in Canada requiring treatment for Diabetic Macular Edema.
Roche Canada is pleased to announce that on 31 October 2022, the CADTH Canadian Drug Expert Committee recommended Vabysmo (faricimab) for public reimbursement.
